Related Experiment Videos
Therapeutic intravenous immunoglobulins
Réal Lemieux1, Renée Bazin, Sonia Néron
1HEMA-QUEBEC, Research and Development and Department of Biochemistry and Microbiology, Faculty of Sciences and Engineering, Laval University, Ste-Foy, Canada G1V 5C3. Real.Lemieux@hema-quebec.qc.ca
Molecular Immunology
|April 15, 2005
Summary
Intravenous immunoglobulins (IVIg) treat autoimmune diseases but their mechanisms remain unclear. Research is ongoing to understand IVIg
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Intravenous immunoglobulins (IVIg) are plasma-derived IgG formulations initially for immunodeficiency.
- IVIg use has expanded to autoimmune and inflammatory diseases, raising concerns about shortages and costs.
- The precise immunomodulatory mechanisms of IVIg are not fully understood.
Purpose of the Study:
- To review proposed mechanisms of IVIg action.
- To discuss active research areas in IVIg immunomodulation.
- To highlight the need for understanding IVIg mechanisms for rational use and potential alternatives.
Main Methods:
- Literature review of clinical observations and experimental models.
- Discussion of proposed Fc, F(ab')(2), and non-IgG related mechanisms.
- Focus on specific research areas: IVIg in Idiopathic Thrombocytopenic Purpura (ITP), effects on B lymphocytes, and role of auto-IgG.
Main Results:
- Multiple, sometimes contradictory, mechanisms have been proposed for IVIg's immunomodulatory effects.
- Research is actively investigating IVIg's impact on ITP, B cell function, and auto-IgG involvement.
- Elucidation of mechanisms is crucial for optimizing clinical application.
Conclusions:
- Understanding IVIg mechanisms is vital for clinical practice and developing substitutes.
- Ensuring long-term availability of plasma-derived IVIg for immunodeficient patients is a priority.
- Further research is needed to clarify the complex immunomodulatory actions of IVIg.